Changes to this Summary (04/11/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that the pilot study showed a 5-year event-free survival rate of 73% for all patients receiving nelarabine and 69% for those patients with a slow early response (cited Dunsmore et al. as reference 10).
Added Ram et al. as reference 32.
Added Leung et al. as reference 54.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.